Clinical trial
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute…
NCT00254787 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00254787 |
|---|---|
| Title | Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients |
| Official title | Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in the Treatment of Patients With Acute Schizophrenia - a Multicentre, Double-Blind, Parallel Group, Randomized Study |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | IR (Immediate-Release) quetiapine fumarate (drug) |
| Enrollment | 30 |
| Start date | Jun 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Nov 17, 2005 |
| Last update posted | Jun 11, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: